A possible motive behind Jason's outrageously low
Post# of 30028
Posted On: 11/12/2014 1:45:11 PM
A possible motive behind Jason's outrageously low estimates is to force Gerald into giving a more "quantitative revenue guidance" for 2015 and 2016. Analysts need more specific guidance from the company in order for them to do any kind of meaningful analysis.
Gerald has tried to not be specific as he is tip toeing LymPro into becoming the Gold Standard Blood Test for Alzheimers. I understand Gerald's desire to not brag about Lympro until he has more patients under his belt.
Jason though has his own agenda and is saying: "Hey Gerald, I've been promoting you guys for a couple of years. Now help me do my job and give me some specific LymPro revenue numbers so I can give a proper analysis and price target for AMBS.
Jason sounds like he still supports AMBS, but is frustrated too by the lack of specific communication.
Gerald has tried to not be specific as he is tip toeing LymPro into becoming the Gold Standard Blood Test for Alzheimers. I understand Gerald's desire to not brag about Lympro until he has more patients under his belt.
Jason though has his own agenda and is saying: "Hey Gerald, I've been promoting you guys for a couple of years. Now help me do my job and give me some specific LymPro revenue numbers so I can give a proper analysis and price target for AMBS.
Jason sounds like he still supports AMBS, but is frustrated too by the lack of specific communication.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼